drugset
drugset / Press release

Janssen Receives Two U.S. FDA Approvals for Simponi aria® (Golimumab) for the Treatment of Adults with Active Psoriatic Arthritis or Active Ankylosing Spondylitis

2017-10-20 · Janssen Research & Development, LLC · original jnj.com ↗

Ad26.COV2.S Golimumab · regulatory

Janssen Receives Two U.S. FDA Approvals for Simponi aria® (Golimumab) for the Treatment of Adults with Active Psoriatic Arthritis or Active Ankylosing Spondylitis October 20, 2017 Janssen Receives Two U.S. FDA Approvals for Simponi aria ® (Golimumab) for the Treatment of Adults with Active Psoriatic Arthritis or Active Ankylosing Spondylitis

The release as fetched from its publisher. jnj.com ↗